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Abstract. Pharmacological correction of the imbalance of zinc is important for a comprehensive 
treatment of microelementoses human. Existing zinc preparations limited in their application, so 
as active ingredients used oxide and zinc sulfate. Nowadays, with the development of physical 
and chemical methods of dispersion increases the amount of information about more effective 
action nanoforms zinc compounds. Via sol-gel method, nanoparticles (2-3 nm) of zinc hydroxide 
were obtained, which were measured by small angle X-ray scattering. The purpose of a 
preliminary assessment of the biological effect, a comparative study of nanoparticles using test 
cultures of bakery yeast, the results of which determined the level of inhibition, which was higher 
than 90%, compared with the figure for the zinc sulfate and the above 145% more compared to 
the zinc oxide. Investigation was performed on the pharmacokinetic characteristics of the 40 
rabbits-males in comparison with that using zinc sulfate, in an enteral or intravenous 
administration at three dose levels: 10, 50 and 100 mg/kg. The time to reach maximum 
concentration of Zn
2 +
 in enteral administration of nanoform was 4 hours, which is faster than that 
of zinc sulfate - 6 hours. The total clearance of nanoparticles increases with dose increases, 
amounting to 9.60±0.38, 13.96±0.24, 15.55±0.12 ml/h, half-life is not a statistically significant 
change. High parameters determined for the absolute bioavailability of zinc in enteral 
administration of zinc hydroxide nanoparticles - 30.33 ± 3.16, 44.39 ± 4.52 and 42.47 ± 3.66%, 
respectively, for doses of 10, 50 and 100 mg/kg. The pharmacokinetic properties when 
administered nanoforms zinc hydroxide and zinc sulfate soluble have no significant difference (at 
10 and 50 mg/kg), which, however, are shown at a dose of 100 mg/kg. Determined a more rapid 
time of onset of maximum concentration for nanoforms, in comparison with zinc sulfate, and high 
parameters absolute bioavailability for zinc in enteral introduction of nanoparticles of zinc 
hydroxide: - 30.33±3.16, 44.39±4.52 and 42.47±3.66%, respectively, with a dosage: 10, 50 and 
100 mg/kg. The pharmacokinetic properties when administered nanoform of zinc hydroxide and 
soluble zinc sulfate have no significant difference (at 10 and 50 mg/kg), which, however, have 
difference at 100 mg/kg. Investigation accumulation dynamics was conducted on 90 rats-males 
Wistar under enteral administration in a dosage of 100 mg/kg, using as comparison compound, 
zinc sulfate. Significantly was selected (p<0.05) the maximum level of accumulation of zinc in 
erythrocyte mass with the introduction of nanoforms of zinc hydroxide. Also significantly was 
selected (p<0.05) the lowest level of accumulation of zinc in liver tissues, compared with those 
groups which were administered zinc sulfate and zinc hydroxide. 
Keywords: zinc, nanoparticles, zinc hydroxide, zinc sulfate, zinc oxide, pharmacokinetics, 
accumulation. 
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Introduction. 
Our days more than 6% of all deaths in the 
world have a correlation with the incidence of 
microelementoses [1]. Zinc deficiency on the 
prevalence of inferior iron deficiency. By 2010, the 
figure connected with zinc deficiency mortality rate 
was 9136 people, with the total number exposed to 
geparinaza people in the world amounted to 1.1 
billion people. [2]. It is important to note that zinc 
deficiency in the human body occurs not as a 
consequence of insufficient supply of food, and due 
to the low bioavailability from dietary sources. In 
addition, zinc deficiency can occur in severe 
diseases: sickle-cell anemia, AIDS, burns, liver 
cirrhosis, and others. 
Some clinical condition associated with zinc 
deficiency, cover the skin, gastrointestinal tract, 
central nervous system, skeletal system and 
reproductive system [3]. Zinc deficiency manifests in 
weight loss, deterioration in the perception of taste 
and smell. Extensive influence on the function of the 
body is due to the structural and catalytic role of Zn
2+
 
to more than 3000 enzymes. [4]. 
To correct the imbalance advisable to use zinc 
supplements [5]. Zinc oxide and sulfate zinc are the 
basic compounds that are part of the most vitamin-
mineral complexes [6, 7]. Search of ways to increase 
therapeutic effect is divided in two areas: the 
traditional combination of zinc compounds to 
enhance the effect, and the search for new 
biologically active compounds among the products of 
modern technology [8]. A promising direction could 
be the application of ground to nanoscale (10
-9
 m) 
zinc compounds. It is known that significantly 
modifies the biological properties of the compound 
change in its physico-chemical properties: size, 
surface morphology and crystal structure [9]. The 
results of pharmacological and biopharmaceutical 
research conducted on laboratory animals, conducted 
for nanoparticles of zinc oxide [10, 11, 12, 13] and 
demonstrate a higher bioavailability parameters, 
compared with the traditional compounds zinc sulfate 
and zinc oxide. 
Thus, the urgent problems of modern clinical 
pharmacology are: study of the interaction between 
the organism and zinc compounds dispersed to 
nanoscale, the study of their pharmacokinetics, the 
study of the distribution between organs and tissues, 
establishing relationships between dose, 
concentrations and efficiency. 
The purpose of this investigation was to study 
the pharmacokinetic properties and bioavailability of 
nanoforms of zinc hydroxide and its distribution 
among tissues and organs in comparison with zinc 
sulfate in the experiment in vivo. 
 
Materials and methods. 
Synthesis of nanoparticles was performed zinc 
hydroxide sol-gel method in an environment of 
absolute ethanol (99.95%). Absolute ethanol was 
used to prepare solutions of zinc acetate dihydrate 
(chemically pure) and lithium hydroxide anhydrous. 
The solutions were merged with the cooling to 0
оС at 
a speed of 2-3 drops per minute. The resulting 
suspension was diluted with distilled water and 
centrifuged to separate the gel that contains 
nanoparticles of zinc hydroxide. The particle size was 
estimated by the method of small angle x-ray 
scattering using an energy dispersive x-ray 
fluorescence spectrometer Shimadzu EDX-800HS. 
Received nanoform of zinc hydroxide was 
subjected to a preliminary investigation in vitro on 
the test culture of Saccharomyces cerevisiae. The 
yeast activity was determined by accelerated method 
of determining the lift force on the State standard of 
the Russian Federation 54731-2011. The average 
samples of bakery compressed yeast was selected 
suspension of yeast with a mass of 0.31 g, which was 
transferred to a porcelain cup with the addition of 
2.5% salt solution, with a volume of 4.8 cm
3
 heated 
to 35
оС. After thorough added with stirring, 7 grams 
of flour for the dough, which indulged in ball shape. 
This ball of dough dropped in a glass of water and 
thermostating at a temperature of 35
оС. The lifting 
force was characterized by a period of time until the 
ascent of the ball, which was calculated in minutes 
and multiplied by an empirical coefficient 3.5. The 
lifting force of the control group (no added 
substances) was calculated as 100% and changes 
were calculated relative to 100%. Increasing the 
value shows a negative effect (increase in time of 
ascent of the ball of dough), with a decreasing value 
shows a negative effect (reducing the time of ascent 
of the ball of dough). For comparison of the effect 
were used: zinc oxide (commercial sample), zinc 
sulfate (soluble crystals) and zinc hydroxide 
(nanoparticles obtained by the sol-gel method).  
Experiments using laboratory animals was 
planned and conducted in accordance with the 
Directive 2010/63/EU the European Parliament and 
of the Council of the European Union for the 
protection of animals used for scientific purposes, 22 
September 2010, Council's Directive 86/609/ЕЕС, 24 
November 1986: "On the coordination of laws, 
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regulations and administrative orders of the 
participating countries regarding the protection of 
animals used for experimental and scientific 
purposes". The animals were kept indoors in 
individual cages with maintaining the specified 
parameters of the microclimate: temperature 20
оС ± 
2
оС, humidity 60% ± 10% and 12-hour lighting 
cycle. Animals received a standard diet of the 
vivarium: extruded complete feed PK-120 and 
filtered drinking water in a quantity ad libitum. 
Animals were placed on 14-day quarantine before the 
manipulation, during which conducted monitoring of 
the clinical condition with daily visual inspection. 12 
hours before the start of the experiment the 
experimental animals were deprived of food. 
Operations and manipulations with animals were 
performed using General anesthesia with intra-
abdominal introduction of an aqueous solution of 
chloral hydrate at a dosage of 300 mg/kg. The killing 
was carried out by means overdose of anesthetic. 
Experimental study of the pharmacokinetic profile 
of nanoscale zinc hydroxide was carried out on 40 
rabbits-males of Chinchilla breed of Federal state 
unitary enterprise "Nursery of laboratory animals 
Rappula". Animals were selected according to body 
weight in the range from 4200 to 4430 grams. 
The study of pharmacokinetic characteristics of 
zinc in a one-time enteral introduction of nanoforms 
of zinc hydroxide was carried out on 10 rabbits, 
which by the criterion of the amount of the drug was 
divided into 4 groups (n=10). Animals using the 
probe was introduced a suspension of nanoparticles 
of zinc hydroxide (in distilled water) in three doses: 
10, 50 and 100 mg/kg (calculated as zinc), 
respectively, in the 1, 2 and 3 group. In the control 
group 4 rabbits were intragastrically administered an 
equivalent volume of distilled water. Similarly, to 
determine the pharmacokinetic properties of the 
compounds-comparison of the sulfate of zinc when 
enteral administered in the same dosage was formed 
4 groups (n=10). 
To determine the parameters of absolute 
bioavailability for nanoforms of zinc hydroxide and 
compounds-comparison of the zinc sulfate a study 
was conducted pharmacokinetic properties under 
conditions of intravenous administration at three 
doses: 10, 50 and 100 mg/kg. Nanoparticles were 
introduced as suspension in isotonic solution of 
sodium chloride. Zinc sulfate was administered as an 
aqueous solution for injection. 
Sampling of blood with a volume of 1 ml was 
performed through a catheter from a regional ear vein 
every 15, 30, 60, 120, 240, 360, 480, 600, 720, 960 
and 1440 minutes. Also the sampling of blood with a 
volume of 1 ml was carried out after intravenous 
injection every 1, 10, 15, 30, 60, 90, 120, 240, 360 
and 720 minutes. Samples in test tubes that were 
treated with lithium heparin, placed in a centrifuge at 
3000 rpm for 15 minutes to separate plasma. Before 
analysis the plasma was frozen and stored at a 
temperature of -28
оС. 
Investigation of the distribution in organs and 
tissues was conducted on 90 " rats-males breed 
Wistar aged 10 weeks and weighing in the range of 
120 – 150 grams. Rats by the criterion of the obtained 
compounds were divided into 4 groups: nanoform of 
zinc hydroxide (group 1), microparticles of zinc 
oxide (group 2), the comparison compound of the 
zinc sulfate (group 3) and control group (group 4). 
Compounds were administered as a suspension (zinc 
hydroxide and zinc oxide) enteral method and in the 
form of a solution (zinc sulfate) at a dosage of 100 
mg/kg (calculated as zinc). Animals received the test 
compound once a day under the scheme: 0 – 24 – 48 
– 72 – 120 – 168 hours. Through 4 hours after the 
administration in an animal specimen using ether 
anesthesia blood sample was obtained from the 
jugular vein. After sacrifice of the animal were 
sampled testes and liver. 
Pre sample preparation for the quantification of 
zinc in biological material was carried out by means 
of mineralization in perchloric acid (72.4%) at a 
temperature 190-210
оС with oxidation by hydrogen 
peroxide (36%). Transparent mineralized evaporated 
to a state of moist salts and subsequently dissolved in 
deionized water and analyzed by atomic absorption 
spectrometry on the spectrometer "SPECTR-5-4" 
(JSC "Soyuztsvetmetavtomatika" number in the state 
register of measuring instruments 13743-04). Before 
the work was carried out the calibration method of 
absolute calibration with using of state standard 
samples of substance of zinc ions (LLC "TSSOVV", 
Russia, State registration number in the registry 
8053-94) with a concentration in the range of 
0.0005 – 1.0 mg/dm3. 
To obtain the characteristics of statistical 
indicators were calculated: the arithmetic mean 
number, standard deviation arithmetic mean number 
(Sd), standard error of the arithmetic mean of the 
number (m), coefficient of variation (CV%). To 
determine the statistical significance of differences 
was used the method of defining the boundaries of 
the confidence interval (t) with an acceptable level of 
p<0.05 for experimental biomedical research. 
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Mathematical calculations and plotting was done 
using the software OriginPro 9.2 (OriginLab, USA) 
and Excel 14 (Microsoft, USA). 
Obtained results and their discussion. 
The weight distribution function of 
inhomogeneity’s in the Dm (d) was calculated along 
the curves of small angular scattering and 
demonstrates showed a predominance of particles of 
zinc hydroxide with a size of 2-3 nm (Fig. 1) 
. 
 
 
Figure 1. The distribution of inhomogeneity’s in the gel containing nanoparticles of zinc hydroxide. 
 
 
For a preliminary assessment of biological 
activity was used a test system from cell cultures 
S.cerevisiae. The system allows simulating the basic 
conditions of membrane transport, with the 
possibility of estimating efficiency without the use of 
special methods. Indicator of biological activity was 
the parameter of the lifting force of the yeast, because 
the fermentation process involved enzymes, localized 
in different parts of the cell. 
Figure 2 shows the obtained dependence of the 
degree of change of the lifting force of the test 
culture S.cerevisiae from the content of the 
compound (calculated as zinc) on 1 gram of yeast 
cells at different concentrations. 
Maximum depressing activity in the lift force 
was observed in the group (figure 2 (1)) 
corresponding to the nanoparticles of zinc hydroxide. 
Maximum observed at 48.39 mg/g and constitutes 
272.83 ± 2.43%. The rate of lift force takes the value 
characteristic of "idle" experience with 3 mg/g. Zinc 
sulfate (figure 2 (2)) exerts a small inhibitory effect 
with increased 144.00±2.48% at 48.39 mg/g and does 
not have statistical differences compared with the 
control group at 12.1 mg/g. The rate of changing 
lifting force (p <0.05) higher for the group, which 
was introduced nanoform of zinc hydroxide than for 
the group, which was administered zinc sulfate at 
concentrations of 48.39, 24.19 and 12.10 mg/g. An 
intermediate position is occupied by a group in which 
a commercial sample of zinc oxide was added to the 
test cultures (Figure 2 (3)), resulting in the inhibition 
effect was maintained at a concentration of 12.1 
mg/g. Values lift changes were statistically 
indistinguishable with zinc sulfate group, since 
dosages 24.19 mg/g. 
Several authors noted the need for the presence of 
a constant concentration of Zn
2+
 in the culture medium 
during the cultivation S.cerevisiae – 10-15 mM. This is 
necessary to maintain enzymatic activity [14] and can 
decrease the lift force (positive effect). The excess of 
zinc can have toxic influence on the culture of yeast, 
decreasing membrane permeability for ions K
+
 and 
inhibiting the activity of glycosidase, increasing the 
value of the lift force. [15]. Formation mechanism of 
inhibitory action of nanoparticles of zinc hydroxide 
based on the formation of reactive oxygen species 
(ROS) within the cell. [16, 17]. The main toxic effect is 
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on the cell membrane, where localized basic proteins 
during alcoholic fermentation. However, the original 
mechanism of damage is formed in the mitochondria, 
which are transported in the nanoparticles absorbed by 
endocytosis. Membrane damage occurs after damage to 
the walls of the mitochondria and after penetration of 
ROS into the cytosol. This inevitably leads to the 
immobilization of enzymes and to increase the lift. The 
increase of the lift force is an inevitable process when 
activating transport nanoforms through the cell wall. 
This allows making a conclusion about the nature of the 
inhibitory action of zinc hydroxide due to its complete 
penetration through the membrane of the yeast cells. 
 
 
 
Figure 2. The rate of change of the lift force according to different mass concentrations of zinc compounds: 1 – nanoform of zinc 
hydroxide, 2 – soluble zinc sulfate, 3 – a commercial sample of zinc oxide, 4 – control group (   , p=0.05, * - differences have 
statistical significance in relation to subsequent group, # - differences have statistical significance against the control group). 
 
Highest activity of zinc hydroxide in the 
experiments in vitro allows hypothesizing the activity of 
nanoforms in vivo. To assess the pharmacokinetic 
parameters of nanoscale zinc hydroxide of the 
experimental animals were administered enteral three 
dosage levels: 10, 50 and 100 mg/kg. For comparative 
evaluation in similar conditions, with an equal dose 
level, compound was administered for comparison of 
zinc sulfate. The results are shown in Figure 3. 
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Figure 3. Pharmacokinetic curves nanoforms hydroxide (A) and zinc sulfate (B) when enteral administered in a dosage of: 10 
(1), 50 (2) and 100 (3) mg/kg. 
 
The main pharmacokinetic parameters were 
calculated by model independent method based on 
the pharmacokinetic curves: AUC0-t (h×μg/ml), 
AUMC (h
2× μg/ml), ClT (ml/h), MRT (hour), Cmax 
(μg/ml), tmax (h), T1/2 (h), and Cmax/AUC0-t (1/hour), fa 
(%).The results are shown in table 1. 
 
Table 1. 
Pharmacokinetic parameters of nanoforms of zinc hydroxide and soluble zinc sulfate after a single enteral introduction 
in three dosages (   ; n=3 (per group)). 
 
Parameters 
Single enteral administration of nanoform of zinc 
hydroxide. 
Single enteral administration of the dissolved zinc 
sulphate. 
Dosage (mg/kg) Dosage (mg/kg) 
10 50 100 10 50 100 
AUC0-t, h×μg/ml 
1040.47 ± 
40.85 
3580.90 ± 
60.86 
6430.28 ± 
49.51 
1260.14 ± 
61.94 
3540.66 ± 
56.03 
6070.54 ± 
70.18 
AUMC,  
h
2×μg/ml 
1243.78 ± 
39.36 
3793.56 ± 
77.23 
6643.93 ± 
52.97 
1472.95 ± 
68.93 
3753.31 ± 
55.99 
6276.82 ± 
73.17 
ClT, ml/h 9.60 ±0.38 13.96 ± 0.24 15.55 ± 0.12 7.92 ±0.39 14.12 ± 0.22 16.47 ± 0.19 
MRT, h 1.19 ± 0.01 1.06 ± 0.01 1.03 ± 0.01 1.17 ± 0.01 1.06 ± 0.01 1.03 ± 0.01 
Cmax, h 120.73 ± 6.47 390.58 ± 10.38 660.47 ± 10.17 169.72 ± 7.63 383.82 ± 25.78 553.86 ± 24.44 
Tmax, h 4 4 4 6 6 6 
Т1/2, h 4.97 ± 0.15 5.92 ± 0.16 5.09 ± 0.12 5.60 ± 0.19 5.49 ± 0.40 5.58 ± 0.34 
Cmax/AUC, 1/h 0.12 ±0.01 0.11 ±0.01 0.10 ±0.02 0.13 ±0.01 0.11 ±0.02 0.09 ±0.02 
Fa, % 30.33 ± 3.16 44.39 ± 4.52 42.47 ± 3.66 33.03 ± 3.55 42.67 ± 5.63 39.51 ± 2.12 
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The maximum concentration of Zn
2+
 in blood 
plasma after administration of compounds has the 
following trends: at a dose of 10 mg/kg Cmax 
(p<0.05) higher for zinc sulfate than for 
nanoparticles of zinc hydroxide (169.72±7.63 
μg/ml and 120.73±of 6.47 μg/ml) at a dose of 50 
mg/kg groups did not have statistically significant 
differences (390.58±10.38 and 383.82±25.78 
μg/ml) at a dose of 100 mg/kg nanoforms of zinc 
hydroxide (p<0.05) have higher maximum 
concentration in comparison with soluble zinc 
sulfate (660.47±10.17 μg/ml and 553.86±24.44 
μg/ml). The time to maximum concentration for 
nanoforms of zinc hydroxide is 4 hours (regardless 
of the administered dose). This figure is higher 
than in groups which were introduced zinc sulfate 
– tmax in which the figure amounted to 6 hours. To 
demonstrate the quantitative assessment eliminable 
substances for each group was calculated total 
clearance (ClT). This parameter is comparable to 
nano-sized zinc hydroxide and compounds-
comparison, which was introduced enteral method, 
increasing with increasing appropriate dosage: 
9.60±0.38, 13.96±0.24, 15.55±0.12 and 7.92±0.39, 
14.12±0.22, 16.47±0.19 ml/h. Values for average 
holding time (MRT) when intragastric introduction 
does not have statistical significant differences for 
zinc sulfate and zinc hydroxide and is not changed 
with increasing dosage. On the basis of area under 
the curve was determined the absolute 
bioavailability (fa) in comparison with 
intravascular administration. Values for nanosized 
hydroxide zinc values for the three doses 
respectively were: 30.33±3.16, 44.39±4.52 and 
42.47±3.66%. These parameters were calculated 
for the comparison compound of the sulphate of 
zinc: 30.03±3.55, 42.67±5.63 and 39.51±2.12%. 
Significantly (p<0.05) higher in the nanoforms of 
zinc hydroxide this parameter is defined for the 
dose of 100 mg/kg. 
When entering the digestive tract, the 
nanoparticles are partially soluble in gastric juice 
to form zinc ions [18, 10]. The efficiency of 
dissolution depends on the particle size, 
determining the surface area that comes in contact 
with acid and from the spatial structure. Insoluble 
nanoparticles can pass through the intestinal wall 
without significant chemical transformations [19]. 
Introduction of small doses (10 mg/kg and 50 
mg/kg) leads to a complete dissolution of the 
administered compound. This is evidenced by the 
maximum concentration that can be compared to 
zinc sulfate. With the introduction of a dose of 100 
mg/kg slow dissolution of nanoforms in the 
stomach (spatial structure of particles of zinc 
hydroxide is described as a colloidal micelle, 
surrounded by a stabilizing shell, consisting of 
counterions). For this reason it is not dissolved in 
the nanoparticles are absorbed intact into the 
systemic circulation. This hypothesis was 
confirmed in experiments on rats. In carrying out 
that after the introduction of its nanoform deposits 
were found in the intestine [20]. The nature of 
absorption explains the more rapid time to 
maximum concentration of nanoforms in the blood 
plasma. Penetration into the systemic circulation in 
the form of particles excludes the time spent on the 
binding of zinc ions with proteins. Meanwhile, a 
part of zinc, converted in a dissolved form, 
provides a slower decay after reaching the 
maximum concentration. 
Investigate pharmacokinetic properties of 
nanoforms of zinc hydroxide and soluble zinc 
sulfate under conditions of intravascular injection 
at doses similar to enteral infusion was performed 
for comparative performance. The pharmacokinetic 
curves are shown in Figure 4. 
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Figure 4. Pharmacokinetic curves nanoforms hydroxide (A) and zinc sulfate (B) when administered intravenously in a dosage: 
10 (1), 50 (2) and 100 (3) mg/kg.
 
 
Based on the pharmacokinetic curves were calculated pharmacokinetic characteristics that given in Table 2. 
 
Table 2 
Pharmacokinetic parameters of zinc hydroxide nanoform and soluble zinc sulfate after single intravascular injection  
of three doses (   ; n=3 (per group)). 
 
Parameters 
Single injection of nanoforms of zinc hydroxide. Single injection of sulfate zinc. 
dosage (mg/kg) dosage (mg/kg) 
10 50 100 10 50 100 
AUC0-t, h× μg/ml 34.13 ± 2.67 80.02 ± 9.45 150.72 ± 11.86 38.00 ± 2.48 82.13 ± 9.79 153.29 ± 10.13 
AUMC, h
2× 
μg/ml 
59.17 ± 1.52 114.26 ± 5.89 150.72 ± 11.86 64.59 ± 4.74 131.01 ± 10.31 257.01 ± 14.79 
ClT, ml/h 291.86 ± 22.27 619.12 ± 73.81 660.77 ± 51.86 262.39 ± 17.41 603.29 ± 70.06 650.48 ± 42.17 
MRT, h 1.00 ±0.05 1.01 ±  0.01 1.01 ±  0.01 1.03 ±0.01 1.00 ±0.02 0.99 ±0.01 
Cmax, h 114.73 ± 4.81 261.27 ± 4.43 396.11 ± 17.44 175.65 ± 10.68 382.13 ± 5.72 593.28 ± 11.41 
Tmax, h 0.016 0.016 0.016 0.016 0.016 0.016 
Т1/2, h 0.34 ±0.10 0.44 ±0.12 0.39 ±0.04 0.13 ±0.01 0.14 ±0.03 0.14 ±0.01 
Cmax/AUC, 1/h 3.34 ± 0.36 3.23 ± 0.43 2.89 ± 0.42 4.42 ± 0.25 4.61 ± 0.60 4.26 ± 0.59 
 
For all groups the maximum concentration of zinc 
ions Zn
2+
 was detected in the blood after 0.016 hours 
after drug administration. Further, there was a sharp 
decrease in the content of zinc ions in the plasma, with 
no statistically significant differences in comparison 
with the control group after 2 hours. These data are 
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consistent with the work of other researchers in which 
the time of occurrence of maximum concentration with 
intravenous administration of nanoparticles of zinc 
oxide was determined for 1 minute [12]. The maximum 
concentration of zinc ions in plasma (p<0.05) higher 
when enteral introduction of nanoforms (compared to 
intravenous) in dosages of 50 and 100 mg/kg (amount: 
390.58±10.38 and 261.27±4.43 μg/ml, 660.47±10.17 
and 396.11±17.44 μg/ml). When comparing the zinc 
levels in the plasma for enteral and intravenous 
administration of soluble zinc sulfate found no 
statistically significant differences (169.72 ± 7.63 and 
175.65 ± 10.68 μg/ml, 383.82 ± 25.78 and 382.13 ± 
5.72 μg/ml, 553.86 ± 24.44 and 593.28 ± 11.41 μg/ml, 
respectively, for a dosage 10, 50 and 100 μg/ml). 
Registered contrast to the maximum 
concentrations after intravenous and intragastric 
administration due to several factors. First, it is the 
ability of particles to aggregate in the bloodstream or 
to adsorption on the surface of red blood cells. [21, 
22]. Was carried out the separation of the plasma in 
order to determine the concentration of zinc, 
therefore, part of nanoforms of zinc hydroxide could 
remain on the surface of red blood cells. We are also 
confirmed (in the experiments on rats) that when 
assessing the distribution of zinc between plasma and 
erythrocyte mass, there is a significant preponderance 
of concentrations in the direction of the erythrocyte 
mass [20]. Second, the rapid recycling units of zinc 
hydroxide in the bloodstream, indicative of relatively 
higher parameters total clearance for the nanoforms. 
To determine the anticipated target organs and to 
assess the dynamics of accumulation of trace element 
concentrations were determined in blood fractions of 
rats: plasma and erythrocyte mass, in the anticipated 
target organs: the testes and the liver (in terms of 
repeated administration of one dose). 
Dynamics of accumulation of zinc ions in the 
blood plasma has a similar trend for each of the three 
groups: statistical significant increase in the 
concentration (p<0.05), which varies from lower levels 
Zn
2+
 after 120 hours (the cancellation period) and after 
the resumption of reception increases (figure 5). This 
effect is the break with the introduction of rats studied 
compounds and shows a high rate of redistribution to 
other organs of zinc, in excess contained in the plasma. 
It is noted for the group treated with nanoparticles, the 
reduction of concentration was minimum (120 hours), 
while in the groups, which were injected microparticles 
of ZnO and comparison compound, the concentration 
Zn
2+
 (4.20±0.12 and 4.22±0.17 μg/ml) returned to the 
values of the control group (3.70±0.13 μg/ml). The 
maximum concentration in the blood plasma of the 
treated group nanoform, at the end of the experiment 
has no statistical significant difference with group, 
receiving the comparison compound (5.63±0.19 and 
6.08±0.12 μg/ml). 
 
 
Figure 5. Dynamics of the accumulation: (μg/ml) in blood plasma of rats: group (a), treated with nanoform zinc hydroxide. 
Group (b) was treated with micro-sized zinc oxide. Group (c) treated with zinc sulfate. 
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Zinc concentration was determined in 
erythrocyte mass of blood (fig. 6). In group A 
(nanoform of zinc hydroxide) there is a significant 
increase of zinc concentration in erythrocyte mass 
after the second dose of compound (5.20±0,11 μg/g 
compared to 4.01±0,11 μg/g in the control group) and 
the lack of concentration decrease after 120 hours 
(during the break). The nature of changes in the level 
of zinc in red blood cell mass during the introduction 
of soluble ZnSO4 has the statistical significance 
(p<0.05) and differed among each of the groups, 
decreasing in the series Zn(OH)2 – ZnO – ZnSO4. For 
zinc sulfate detected a relatively low ability to 
accumulate in red blood cell mass and is 
characterized by the reduction of zinc concentration 
to 4.24±0.17 μg/g at 120 hours (during the break). 
When resuming the introduction of the compounds 
value increases and by the end of the experiment is 
5.12±0.11 μg/g. In the groups treated with 
nanoparticles Zn(OH)2 and ZnO, these values are 
10.13±0.11 μg/g and 8.58±0,21 μg/g. 
 
Figure 6. Dynamics of the accumulation Zn
2+
 (μg/g) in erythrocyte mass of blood of rats: Group (a) receiving nanoform zinc 
hydroxide. Group (b) treated with micro-sized zinc oxide. Group (c) treated with zinc sulfate. 
 
Dynamics of bioaccumulation in erythrocyte 
mass (fig. 6), there is a significant increase in 
concentration after 24 hours (two cycles) after 
ingestion of nanoparticles of zinc oxide and decrease 
in zinc level within the cancellation period of the 
treatment. This result is due to two factors: first, the 
relatively low absorption of nanoparticles in the gut 
and second, the formation of a pool of zinc on the 
inner surface of the intestinal wall, as reported in the 
literature [23]. This was indirectly confirmed during 
the autopsy, which in the intestine of rats were found 
to have extensive deposits nanoforms. The total 
concentrations for groups A and b was higher than 
that of blood plasma, which determines the presence 
of adsorption of particles on the surface of red blood 
cells (this is consistent with literature data) [22]. 
The relatively low level of bioaccumulation of 
nanosized zinc hydroxide in liver tissues compared to 
the zinc sulfate is an advantage of the compounds 
(figure 7). 
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Figure 7. Dynamics of the accumulation Zn
2+
 (μg/g) in liver tissues of rats: Group (a) receiving nanoform zinc hydroxide. 
Group (b) treated micro zinc oxide. Group (C) treated with zinc sulfate. 
 
 
The literature describes cases of hepatotoxicity 
because of active accumulation of zinc in liver 
tissue with the introduction of experimental 
animals of nanoparticles of zinc oxide [24]. In the 
interval of 4 hours has been a slight increase in 
zinc content. The increase subsequently decreases, 
and further noted a small increase. In the group 
where rats were administered zinc oxide, after 168 
hours the concentration Zn
2+
 in the liver exceeds 
the concentration in the control group is 2.5 times. 
This result is consistent with the literature data 
[25]. For compounds-comparison (ZnSO4) to the 
end of the experiment the obtained data exceeds 
2.5 times the concentration of zinc in the liver 
compared with the control group. 
The importance of the influence of zinc ions 
on the reproductive function for the chosen 
compounds was also assessed the results of 
accumulation in the tissues of the testes (figure 8). 
There was a dramatic increase of zinc 
concentration in the testes in the group that received 
nanoparticles of zinc hydroxide. Through 168 hours 
indicator reaches a value of 10.24±0.21 μg/g. These 
values are comparable with the group that was 
administered the sulfate of zinc. Indicator by the end 
of the experiment was 10.34±0.14 μg/g. The increase 
of zinc concentration in the group C marked after 72 
hours, and in group A the increase was observed 
immediately after the introduction. The group that 
received microparticles of zinc oxide, shows a slight 
increase in the concentration of zinc ions in the 
testes, which remains at the same level throughout 
the experiment, and after 168 hours is 4.06±0.12 μg/g 
in the control group, the rate of growth of the 
concentration of zinc ions in the testes is 3.67±0.12 
μg/g. Showed a high tendency to the accumulation of 
nanoscale compounds of zinc, comparable to the 
soluble ionized compound and is related to the size of 
the particles that overcome hematoma testicular 
barrier consisting of Sertoli cells [26]. For zinc 
sulfate, which is absorbed in form of ions, requires 
binding with proteins-carriers and the completion of a 
number of other lengthy stages, with the result that 
there may be an accumulation of only 120 hours. 
Polling transmission hematoma testicular barrier does 
not give ions of the zinc to penetrate the seminiferous 
tubules while increasing the overall level of zinc in 
the body. [27]. Microparticles of ZnO cannot 
effectively overcome the barrier, consisting of 
interstitial cells. 
Conclusion. 
The first stage was reproduced by the Sol-gel 
method of synthesis. The results were obtained for 
the gel containing nanoparticles of zinc hydroxide. 
The study of size distribution it was found that 80% 
of the particles belong to the range 2-3 nanometer. 
Received nanoform was studied in vitro in 
comparison with soluble zinc sulphate and zinc oxide 
(commercial sample on the test culture S.cerevisiae. 
The data obtained demonstrate a high level of inhibition  
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Figure 8. Dynamics of the accumulation Zn
2+
 (microgram/gram) in tissues of the testes of rats: Group (A) receiving nanoform 
zinc hydroxide. Group (b) treated with micro-sized zinc oxide. Group (c) treated with zinc sulfate. 
 
of the complex of the alcoholic fermentation, enzymes 
in yeast cells by nanforms. This made the assumption of 
a high biological activity of nanoparticles of zinc 
hydroxide due to more intensive transport across the 
plasma membrane of cells. 
In the course of the pilot study in rabbits was 
determined the main parameters of the 
pharmacokinetics of zinc in the introduction to 
nanoforms of zinc hydroxide and form soluble zinc 
sulfate (comparison compound). The time to reach 
maximum concentration of Zn
2+
 in enteral 
administration of nanoform was 4 hours, which is faster 
than that of zinc sulfate - 6 hours. The total clearance of 
nanoparticles increases with dose increases, amounting 
to 9.60±0.38, 13.96±0.24, 15.55±0.12 ml/h, half-life 
have not a statistically significant change. The 
maximum concentration of zinc ions in the blood 
plasma when intravenously nanoforms hydroxide 
(p<0.05) lower compared to the enteric introduction and 
is 261.27±4.43 and 390.58±10.38 μg/ml at a dose of 50 
mg/kg, 396.11±17.44 and 660.47±10.17 μg/ml for 
doses of 100 μg/g. It also identified the parameters 
absolute bioavailability for nanoforms of zinc 
hydroxide: 30.33±3.16, 44.39±4.52 and 42.47±3.66%, 
respectively, for doses of 10, 50 and 100 mg/kg. We can 
state that in the dosages of 10, 50 mg/kg 
pharmacokinetic properties of compared compounds do 
not have significant differences, which are shown only 
at 100 mg/kg. 
A comparative study of accumulation 
parameters of nanoparticles in blood fractions, liver 
and testes identified target organs with affinity to the 
nanoscale hydroxide zinc compared to zinc sulfate. 
Erythrocyte mass of the testes is an advantage of the 
obtained compounds. A low level of accumulation in 
the liver compared with the comparison compound 
may indicate smaller forms of hepatotoxicity, which 
is typical for zinc sulfate. 
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